BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 29
• 30

• BioCapital

  American Association for Clinical Chemistry Release: FDA Director For Diagnostic Tests To Discuss The Agency’s Proposed Framework To Oversee Laboratory Developed Tests

  September 9, 2014

   · 

  3 min read
• SuppreMol’s Clinical Data In SLE For Its Lead Product SM101 Accepted For Presentation At The 2014 ACR / ARHP Annual Meeting In Boston

  September 9, 2014

   · 

  2 min read
• Biotech Bay

  Exelixis, Inc. To Present At The Morgan Stanley Global Healthcare Conference On Tuesday, September 9

  September 9, 2014

   · 

  1 min read
• Biotech Beach

  OncoSec Medical Inc. To Present Data At ESMO 2014 Congress

  September 9, 2014

   · 

  1 min read
• Bio NC

  Massachusetts General Hospital Release: 2014 Chabner Colloquium Focuses On Collaboration In Cancer Trials

  September 9, 2014

   · 

  4 min read
• F2G Ltd, The UK-Based Antifungal Drug Discovery And Development Company, Today Announced A Major Funding Award From The Technology Strategy Board’s Biomedical Catalyst

  September 9, 2014

   · 

  3 min read
• Deals

  ReproCELL Acquires The iPS Cell Business Unit Of Stemgent, Inc.

  September 9, 2014

   · 

  1 min read
• Drug Development

  Spectrum Pharmaceuticals, Inc. Makes Decision To Advance SPI-2012, A Novel Long-Acting GCSF, To Phase 3 Due To Positive Phase 2 Results In Its Collaboration Program With Hanmi Pharmaceutical, Co., Ltd

  September 9, 2014

   · 

  1 min read
• Genetown

  Mersana Therapeutics, Inc. Strengthens Antibody-Drug Conjugate Intellectual Property Position With Issuance Of Three Additional U.S. Patents

  September 9, 2014

   · 

  1 min read
• Drug Development

  CytRx Corporation Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas

  September 9, 2014

   · 

  1 min read